Our medicines
We believe in the power of science to tackle some of the most challenging diseases of our time. We have a long history of developing life-saving medicines and a promising pipeline to shape the next generation of treatment options across multiple indications and therapeutic areas.
This visual gives an overview of the reimbursed medicines of Bristol Myers Squibb in Belgium in October 2024.
This is an overview of all Bristol Myers Squibb medicines, both reimbursed and non-reimbursed.
ABECMA (idecabtagene vicleucel)
ABRAXANE (paclitaxel)
AZACTAM (aztreonam)
BARACLUDE (entecavir)
BREYANZI (lisocabtagene maraleucel)
CAMZYOS (mavacamten)
ELIQUIS (apixaban)
EMPLICITI (elotuzumab)
IMNOVID (pomalidomide)
INREBIC (fedratinib)
KENACORT-A (triamcinolonacetonide)
KRAZATI (adagrasib)
ONUREG (azacitidine)
OPDIVO (nivolumab)
OPDUALAG (nivolumab and relatlimab)
ORENCIA powder for concentrate for solution for infusion (abatacept)
ORENCIA solution for injection in a pre-filled syringe (abatacept)
ORENCIA solution for injection in pre-filled pen (abatacept)
REBLOZYL (luspatercept)
REVLIMID (lenalidomide)
THALIDOMIDE BMS (thalidomide)
SOTYKTU (deucravacitinib)
SPRYCEL (dasatinib)
VIDAZA (azacitidine)
YERVOY (ipilimumab)
ZEPOSIA (ozanimod)